Sales enablement for agencies: how to productise the offering for healthcare and life sciences in the Middle East
The service design, pricing, and delivery model for running sales enablement as a productised offering inside a services firm. Written for commercial leaders at healthtech, medtech, and life-sciences companies in the Middle East.
This edition of the Growth Broker playbook is written for commercial leaders at healthtech, medtech, and life-sciences companies operating in the Middle East. In this market, Middle Eastern buyers reward in-person credibility, sovereign fit, and patient sequencing, so the way you install sales enablement has to be shaped to that reality from day one.
Sales enablement is one of the highest-margin offerings an agency can add in 2026. It is putting the exact asset a rep needs in front of the exact deal at the exact stage, and clients will pay a premium for the discipline they cannot install themselves.
Productise around outcome, not activity. Sell ramp time for new reps to first closed-won moving to a defined level in a defined window, not a monthly retainer of vague ops.
Delivery pod: one strategist, one operator, one editor. Fewer people than that risks quality; more than that dilutes margin.
Inside healthcare and life sciences, the binding constraint is almost always regulated-sale cycle length, not intent, and in the Middle East it is compounded by the fact that senior-relationship access, not product is what actually gates growth. Sales enablement is only useful here when it is pointed at both constraints at once.
Onboarding takes two weeks: diagnosis, list build, trigger definition, kill criteria. Do not ship anything live before the diagnosis is signed off.
Pricing: outcome-linked base plus a monthly ops fee. The base rewards results; the ops fee funds the delivery pod.
Client failure mode: content libraries no one opens. Write it into the engagement letter as a shared risk, not something you absorb quietly.
The agencies making the most from sales enablement are the ones with the tightest playbook. Documented, versioned, and improved every quarter.
Concretely for healthcare and life sciences in the Middle East: the healthcare teams that install this get past procurement instead of dying in it, and one sovereign or family-office win in the Middle East justifies a full year of program spend. That is the reason it is worth installing sales enablement deliberately for this market rather than importing a playbook designed for somewhere else.
Frequently asked questions
Sales · healthcare · Middle East — answered
- Does sales enablement work for healthcare and life sciences in the Middle East?
- Yes — provided it is pointed at regulated-sale cycle length, not intent and adapted to the fact that in the Middle East, Middle Eastern buyers reward in-person credibility, sovereign fit, and patient sequencing. The healthcare teams that install this get past procurement instead of dying in it.
- How should agencies price sales enablement?
- Outcome-linked base plus a monthly ops fee. Avoid pure retainer.
- What is the minimum delivery pod?
- Strategist, operator, editor. Three roles, not necessarily three headcount at small scale.
- How long is agency onboarding for sales enablement?
- Two weeks: diagnosis, list, trigger, kill criteria.
- What client behaviour breaks the engagement?
- Content libraries no one opens — bake shared risk into the contract.
- What is the Middle East-specific pitfall when running sales enablement for healthcare?
- Importing a playbook that was built for another market. In the Middle East, Middle Eastern buyers reward in-person credibility, sovereign fit, and patient sequencing — the install has to reflect that.
Growth Broker editorial
Filed under sales · healthcare · middle east